



Memorandum

Date: July 10, 2026
To: Healthcare Practitioners
From: Insured Health Services
Subject: Formulary Updates July 2026

Dear Healthcare Practitioner,

Semaglutide Generics

- Generic semaglutide products will be added to the formulary effective **July 10, 2026**.
- **Ozempic** will remain as a full benefit on the formulary until further notice.

Jardiance, Synjardy and Invokana

- The eligibility criteria for these medications have been updated to improve access for eligible patients.
- Please go to the Yukon Drug Formulary to review new criteria
<https://apps.gov.yk.ca/apexprd/r/drug/drug-formulary-public/home>
- Reminder that dapagliflozin is an open benefit

Freestyle Libre 3 Sensor and Reader

- If client has been approved for Freestyle Libre they are eligible for Freestyle Libre 3. Please call Extended Benefits to update client's profile.
- Eligible individuals will have coverage for up to a maximum of 1 reader per 3-year benefit period and 25 sensors for each benefit year.

Reminder: Yukon National Pharmacare Plan (YNPP)

- The Yukon National Pharmacare Plan (YNPP) is the **first and 100% payer** for eligible benefits. Any remaining balance must not be charged to the client.
- If there are issues with claim adjudication, your first point of contact should be **Pacific Blue Cross (PBC)**. PBC will provide guidance and advise whether additional information is required.
- If directed to contact Extended Benefits, please fax the required documentation to Extended Benefits for review.

Contact Information:

Chronic Disease and Disability Benefits: 867-667-5092

Pharmacare and Extended Benefits: 867-667-5403 or 867-667-8494

Insured Health Services | Chronic Diseases and Disability Benefits | Pharmacare and Extended Benefits